Nicholas J. Slipek

CRISPR/Cas9-Based Positive Screens for Cancer-Related Traits.

SEMA4C is a novel target to limit osteosarcoma growth, progression, and metastasis.

Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editors.

Author Correction: Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editors.

PLX3397 treatment inhibits constitutive CSF1R-induced oncogenic ERK signaling, reduces tumor growth, and metastatic burden in osteosarcoma.

Implication of ZNF217 in accelerating tumor development and therapeutically targeting ZNF217-induced PI3K-AKT signaling for the treatment of metastatic osteosarcoma.

CRISPR-Cas9 cytidine and adenosine base editing of splice-sites mediates highly-efficient disruption of proteins in primary and immortalized cells.

Internal checkpoint regulates T cell neoantigen reactivity and susceptibility to PD1 blockade.

A Pan-RNase Inhibitor Enabling CRISPR-mRNA Platforms for Engineering of Primary Human Monocytes.

Cas9-induced targeted integration of large DNA payloads in primary human T cells via homology-mediated end-joining DNA repair.

Precision Enhancement of CAR-NK Cells through Non-Viral Engineering and Highly Multiplexed Base Editing.

Evolution of the clinical-stage hyperactive TcBuster transposase as a platform for robust non-viral production of adoptive cellular therapies.

Engineering memory T cells as a platform for long-term enzyme replacement therapy in lysosomal storage disorders.

Precision enhancement of CAR-NK cells through non-viral engineering and highly multiplexed base editing.